1. As of noon trading, Novartis ( NVS) is up $0.60 (0.82) to $73.85 on average volume Thus far, 696,053 shares of Novartis exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $73.58-$74.22 after having opened the day at $73.71 as compared to the previous trading day's close of $73.25.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $177.4 billion and is part of the health care sector. The company has a P/E ratio of 18.8, above the S&P 500 P/E ratio of 17.7. Shares are up 15.7% year to date as of the close of trading on Friday.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Flagged As Strong On High Volume

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

The 10 Highest Dividend Health Care Stocks Are Not All Buys

5 Hated Stocks You Should Love This Earnings Season